Skip to main content

Table 1 Effects of LUF6000 on the potency (-logEC50) and maximum effect (Emax) at the A3 AR of structurally diverse ligands measured with a [35S]GTPγS binding assay

From: Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000

Ligands

Emax (%)

-logEC50 (M)

Cl-IB-MECA

50.1 ± 2.4

7.52 ± 0.11

+LUF 0.1 μM

60.4 ± 3.7

7.62 ± 0.12

+LUF 0.3 μM

70.5 ± 5.2

7.54 ± 0.09

+LUF 1.0 μM

82.4 ± 7.3

7.55 ± 0.10

+LUF 3.0 μM

122 ± 3

7.20 ± 0.06

+LUF 10 μM

125 ± 2

7.21 ± 0.06

NECA

100 ± 3

6.79 ± 0.06

+LUF 1.0 μM

119 ± 7

6.81 ± 0.10

+LUF 10 μM

134 ± 5

6.61 ± 0.07

MRS541

24.3 ± 2.9

7.48 ± 0.31

+LUF 0.1 μM

30.0 ± 1.7

7.43 ± 0.25

+LUF 0.3 μM

45.0 ± 7.0

7.55 ± 0.22

+LUF 1.0 μM

72.5 ± 7.6

7.39 ± 0.16

+LUF 3.0 μM

116 ± 8

7.06 ± 0.11

+LUF 10 μM

121 ± 6

6.99 ± 0.11

MRS542

5.6 ± 2.5

NA

+LUF 0.1 μM

16.4 ± 3.1

NA

+LUF 0.3 μM

34.2 ± 5.4

6.41 ± 0.47

+LUF 1.0 μM

51.7 ± 4.1

7.12 ± 0.20

+LUF 3.0 μM

69.2 ± 4.5

7.14 ± 0.15

+LUF 10 μM

91.1 ± 4.1

6.82 ± 0.11

LUF5833

35.2 ± 5.2

6.02 ± 0.26

+LUF 0.1 μM

63.8 ± 5.2

5.91 ± 0.14

+LUF 1.0 μM

92.7 ± 9.7

5.92 ± 0.18

+LUF 10 μM

102 ± 7.6

5.99 ± 0.13

MRS1220

NA

NA

+LUF 10 μM

NA

NA

  1. The Emax of NECA in the absence of LUF6000 was expressed as 100%. Results are expressed as mean ± S.E. LUF, LUF6000; NA, not applicable.